Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients.
OBJECTIVE
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is associated with atherosclerosis. This study was to investigate the changes of circulating TRAIL and its association with flow-mediated endothelium-dependent arterial dilation (FMD) before and after diabetic treatment in newly diagnosed type 2 diabetes.


METHODS
The study subjects included 55 newly diagnosed type 2 diabetes and 52 healthy subjects. Circulating TRAIL concentration was measured by an ELISA, and high-resolution ultrasound was used to measure FMD of brachial artery.


RESULTS
The circulating TRAIL in patients before treatment was 64·46 pg/ml, which was significantly lower than that in control (80·70 pg/ml, P < 0·001). After 6 months of diabetic treatment, TRAIL level increased markedly (75·11 pg/ml), which was still lower than that in control (P < 0·001). FMD was reduced compared with controls at baseline and increased after diabetic therapy (P < 0·001). In multivariate analysis, circulating TRAIL was significantly associated with FMD, fasting blood glucose (FBG), 2-h blood glucose (2-h BG), haemoglobinA1c (HbA1c) and C-reactive protein (CRP) at baseline (P < 0·01). The absolute change in TRAIL was correlated with the changes in FMD, FBG, 2-h BG, HbA1c and CRP (P < 0·01) before and after diabetic treatment.


CONCLUSIONS
Circulating TRAIL level decreased in newly diagnosed type 2 diabetes and increased after 6 months of diabetic treatment significantly. The circulating TRAIL level is positively associated with endothelial function. Our data showed that circulating TRAIL level may be a protective maker of endothelial function in type 2 diabetes.
Department of Endocrinology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei, China.
Guangda
G
Xiang
Junxia
J
Zhang
Yue
Y
Ling
Linshuang
L
Zhao
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000503:physiopathology*; D002097:C-Reactive Protein / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000000981:diagnostic imaging / Q000503:physiopathology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D015999:Multivariate Analysis; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000097:blood*; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography
D001786:Blood Glucose; D002097:C-Reactive Protein; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human